相关实验视频

Updated: Jan 17, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

在状细胞癌中,PRMT1抑制目标是BNC1-依赖的增殖

Rafik Boudra¹, Bethany L Patenall¹, Sandra King²

¹Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA; Department of Dermatology, Harvard Medical School, Boston, Massachusetts, USA.

The Journal of investigative dermatology

|September 17, 2025

概括

研究人员确定了基础核素1作为状细胞癌 (SCC) 的关键转录因子. 针对其辅因子PRMT1,抑制了SCC的扩散,提供了一个潜在的新治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

转录因子复合体调节细胞功能,并且在状细胞癌 (SCC) 等癌症中常常受到失调.
识别这些复杂物体内的新目标对于开发新的癌症疗法至关重要.

研究的目的:

发现对SCC维护至关重要的新型转录复合体.
确定具有催化活动的目标,用于SCC的潜在治疗干预.

主要方法:

在SCC和非SCC瘤之间对基因表达的比较分析.
识别特定于SCC的转录因子.
对已识别因素的直接转录标的分析.
对蛋白质与蛋白质相互作用的研究 (基础核素1和PRMT1).
评估PRMT1抑制剂对SCC增殖和基因程序的疗效.

主要成果:

巴索努克林1被确定为一种高度表达的,SCC特异的转录因子.
巴索努克林1控制SCC中的增殖,分化和迁移轴.
它激活增殖基因,同时抑制FRA1依赖的迁移和IRF6依赖的分化.
巴索努克林1与PRMT1相互作用,激活细胞周期基因.
PRMT1 抑制剂可以阻止 SCC 扩散,但不会影响促发基因的抑制.

结论:

巴索努克林1通过调节关键细胞过程,在SCC瘤的维持中起着至关重要的作用.
用抑制剂向辅因子PRMT1提供了一个阻止SCC增殖的特定策略.
这种方法可以通过辅因子抑制向原源性活动,而不会促进瘤的进展.

关键词:

基本核素1 (BNC1) 是一种基本核素.非黑色素瘤皮肤癌 (NMSC)蛋白质阿尔金宁是一种蛋白质.状细胞癌 (SCC) 是一种甲基转移酶1 (PRMT1) 是一种

更多相关视频

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells

Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells

Published on: August 7, 2021

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

The Retinoblastoma Gene

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Negative Regulator Molecules

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...